Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Neoplasms 28Lung Neoplasms 24Neoplasm Metastasis 12Mesothelioma, Malignant 11Mesothelioma 10Colorectal Neoplasms 10Ovarian Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Melanoma 5Head and Neck Neoplasms 5Breast Neoplasms 5Adenocarcinoma of Lung 5Pancreatic Neoplasms 4Carcinoma 4Advanced Cancer 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Lymphoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Advanced Solid Tumors 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2

Interventions

Ipilimumab 10Nivolumab 9Interleukin-2 5Cyclophosphamide 5pembrolizumab 3incomplete Freund's adjuvant 3fludarabine phosphate 3Radiosurgery 3Melphalan 3ADI PEG20 3sotrastaurin 2fludarabine 2Specimen Handling 2Ranibizumab 2Magnetic Resonance Spectroscopy 2MART-1 Antigen 2CTLA-4 Antigen 2Biopsy 2utomilumab 1tocilizumab 1siremadlin 1sargramostim 1ruxolitinib 1relatlimab 1pentetreotide 1obinutuzumab 1montanide ISA 51 1lifileucel 1gp100 Melanoma Antigen 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uveal Melanoma × Pemetrexed × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡